A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
Phase of Trial: Phase III
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Aug 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 19 Jul 2012 Planned end date changed from 1 Apr 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.